AbbVie’s Qulipta (atogepant tablets) has been approved for the preventive treatment of episodic migraine in adults. In the pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled, ...

Oral CGRP inhibitors made by AbbVie and Biohaven Pharmaceuticals are quickly gaining share in the migraine market. But unlike their injectable peers, the two oral options have their prevention labels ...

AbbVie’s Qulipta has gained an edge in the heated migraine market thanks to a new approval to prevent chronic migraines. The new FDA nod makes the pill the only oral calcitonin gene-related peptide ...

Qulipta is a brand-name oral tablet that prevents occasional and chronic migraine episodes. Common side effects include nausea, constipation, and fatigue. Most side effects from Qulipta are mild.

QULIPTA's expanded chronic migraine indication is based on the pivotal Phase 3 PROGRESS trial evaluating QULIPTA 60 mg once daily in adult patients with chronic migraine, which met its primary ...

AbbVie ABBV announced that the phase III study — PROGRESS — evaluating its oral calcitonin gene-related peptide (“CGRP”) receptor antagonist, Qulipta (atogepant) — as a preventive treatment for ...

Qulipta (atogepant), a medication approved in the U.S. for the prevention of episodic migraine, has now been approved for chronic migraine prevention, too. Qulipta’s maker, AbbVie, announced the ...